- Home
- AGIO vs BCSF Comparison
AGIO vs BCSF Comparison
Compare AGIO & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- BCSF
- Stock Information
- Founded
- AGIO 2007
- BCSF 2015
- Country
- AGIO United States
- BCSF United States
- Employees
- AGIO N/A
- BCSF N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- BCSF Finance/Investors Services
- Sector
- AGIO Health Care
- BCSF Finance
- Exchange
- AGIO Nasdaq
- BCSF Nasdaq
- Market Cap
- AGIO 1.4B
- BCSF 1.2B
- IPO Year
- AGIO 2013
- BCSF 2018
- Fundamental
- Price
- AGIO $27.66
- BCSF $14.96
- Analyst Decision
- AGIO Buy
- BCSF Hold
- Analyst Count
- AGIO 8
- BCSF 4
- Target Price
- AGIO $56.57
- BCSF $17.25
- AVG Volume (30 Days)
- AGIO 745.1K
- BCSF 443.2K
- Earning Date
- AGIO 05-01-2025
- BCSF 05-05-2025
- Dividend Yield
- AGIO N/A
- BCSF 0.80%
- EPS Growth
- AGIO N/A
- BCSF N/A
- EPS
- AGIO 11.64
- BCSF 1.85
- Revenue
- AGIO $36,498,000.00
- BCSF $292,653,000.00
- Revenue This Year
- AGIO $41.13
- BCSF N/A
- Revenue Next Year
- AGIO $234.96
- BCSF N/A
- P/E Ratio
- AGIO $2.38
- BCSF $8.09
- Revenue Growth
- AGIO 36.07
- BCSF N/A
- 52 Week Low
- AGIO $23.42
- BCSF $13.20
- 52 Week High
- AGIO $62.58
- BCSF $19.21
- Technical
- Relative Strength Index (RSI)
- AGIO 44.94
- BCSF 40.53
- Support Level
- AGIO $26.87
- BCSF $13.78
- Resistance Level
- AGIO $28.24
- BCSF $15.08
- Average True Range (ATR)
- AGIO 1.94
- BCSF 0.68
- MACD
- AGIO 0.22
- BCSF -0.01
- Stochastic Oscillator
- AGIO 66.15
- BCSF 48.62
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes, First Lien Senior Secured Loan, Preferred Equity, Equity Interest, and Second Lien Senior Secured Loan among others.